TcrossGlobal

Aspirin-Free Antithrombotic Therapy After PCI: The STOPDAPT-3 Trial

[ESC Congress 2023] The STOPDAPT-3 trial showed that in patients with ACS or high bleeding risk (HBR), single-agent prasugrel antiplatelet therapy after PCI with DES was not superior to two-agent antiplatelet therapy (DAPT) in reducing severe bleeding and was noninferior in assessing cardiovascular events. Dr. Masahiro Natsuaki of Saga University, presented in a Hot Line session at ESC Congress 2023.

The STOPDAPT-3 trial enrolled 6,002 patients with ACS or HBR undergoing PCI with cobalt-chrome-evero...

Continue reading this article

Select an option below:

Free Registration
Already have an account?
Log In

Introducing the main contents

Conference Reports

Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!

Complex PCI Cases

Features case reports on patients with complex lesions encountered in daily clinical practice.

Live Demonstration CoursesComing soon

In this section you will find live videos of catheter interventions for complex lesions.

What is TCROSS NEWS GLOBAL?

TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.

Learn more about TCROSS NEWS Global

This website is automatically translated using Google Translate.